Arbios Systems, Inc. Informational Review Issued by Scimitar Equity Research, Inc.
January 17 2007 - 8:30AM
PR Newswire (US)
BOSTON, Jan. 17 /PRNewswire/ -- Scimitar Equity Research, Inc.
(Scimitar) today issued a review on Arbios Systems, Inc.
(NASDAQ:ABOS)(OTC:ABOS) Bulletin Board entitled "Developing
Multiple Products to Meet the Unmet Medical Needs of Patients in
Liver Crisis". Arbios Systems, Inc is a pure play in the
development of treatments for patients suffering from
acute-on-chronic or acute liver failure. At present, no direct
treatment for liver failure is available. ABOS.OB has two
innovative, proprietary liver-assist product candidates in clinical
development: SEPET(TM), a proprietary system that selectively
filters the blood for patients with acute- on-chronic liver
failure, currently in a Phase 1/2 feasibility study with positive
interim data; and HepatAssist(TM), a unique bioartificial liver
system that fully replaces human liver function, in patients with
acute liver failure, currently awaiting to re-start Phase 3
clinical development. The analyst research review is available on
Scimitar's website: http://www.scimitarequity.com/. Scimitar Equity
Research, Inc. provides sponsored equity research of the healthcare
industry for the institutional and investment communities. We
certify that all the views expressed in this review, accurately
reflect our personal views about ABOS.OB (Nasdaq; OTC Bulletin
Board: BB) and its or their securities. No part of our compensation
was, is, or will be, directly or indirectly, related to the
specific recommendations or views contained in this review and we
will not have any investment banking relationships or personal
investment in any sponsored company. Investors are advised that
this analysis and review is issued solely for informational
purposes and is not to be construed as an offer to sell or the
solicitation of an offer to buy. Scimitar was paid for preparing
this review. This analysis and review does not have regard to the
specific investment objectives, financial situation and the
information contained herein is based on sources that we believe to
be reliable but is not guaranteed by us as being accurate. Any
opinions expressed are statements of our own judgment as of the
date of publication and are subject to change without notice.
Please read all our important disclosures. CONTACT: Scimitar Equity
Research, Inc. Henry W. McCusker Director of Research phone: (617)
559-1080 fax: (617) 559-1083 e-mail: DATASOURCE: Scimitar Equity
Research, Inc CONTACT: Henry W. McCusker, Director of Research for
Scimitar Equity Research, Inc., +1-617-559-1080, FAX
+1-617-559-1083, Web site: http://www.scimitarequity.com/
Copyright